Service de Gynécologie-Obstétrique, Hôpital NOVO, site Pontoise, 6 Avenue de l'Ile de France, Cergy-Pontoise, Cedex 95303, France; Université Sorbonne Paris Nord, UFR SMBH, 1 rue de Chablis, Bobigny, 93000, France.
Service de Gynécologie-Obstétrique, Hôpital NOVO, site Pontoise, 6 Avenue de l'Ile de France, Cergy-Pontoise, Cedex 95303, France; USRC, Hôpital NOVO site Pontoise, 6 Avenue de l'Ile de France, Cergy-Pontoise, Cedex, 95303, France.
Diabetes Metab. 2024 Jan;50(1):101502. doi: 10.1016/j.diabet.2023.101502. Epub 2023 Dec 6.
The aim of the TELESUR-GDM study was to demonstrate the non-inferiority of the onset of maternal, fœtal, and neonatal complications for patients with gestational diabetes mellitus (GDM) monitored by myDiabby HealthcareⓇ (app group) compared to patients with a classical glycaemic blood monitoring by diary (control group).
TELESUR-GDM was a retrospective, monocentric, and non-inferiority study including 349 patients in the app group and 295 patients in the control group. The primary outcome was a composite score based on maternal, foetal, and neonatal complications. The statistical analysis used chi square or Student t tests for categorical or continuous variables, and Dunnett-Gent test for non-inferiority.
In the app and control groups, 46.3 % and 53.7 % of the patients respectively, observed complications. Non-inferiority of telemonitoring by application vs diary was confirmed (odds ratio=0.79 [95 % CI 0.58;1.07], P < 0.001). Caesarean section, labour induction, and insulin treatment rates were: 20 vs 23 % (P = 0.4), 36 vs 28 % (P = 0.047), and 22 vs 23 % (P = 0.8) in the app vs control group, respectively. Macrosomia, intrauterine growth restriction, neonatal hypoglycaemia, and neonatal jaundice rates were: 4.3 vs 6.1 % (P = 0.4), 6.9 vs 3.1 % (P = 0.04), 1.7 vs 14 % (P < 0.001), and 8.6 vs 1.0 % (P < 0.001), in the app versus control group, respectively.
GDM glycaemic telemonitoring compared to patients with classic glycaemic monitoring by diary was not inferior in terms of maternal, fœtal, and neonatal complications. Neonatal hypoglycaemia, a life-threatening event, was significantly reduced despite the observation of more neonatal jaundice cases.
TELESUR-GDM 研究的目的是证明通过 myDiabby Healthcare Ⓡ(应用组)监测的妊娠期糖尿病(GDM)患者的母体、胎儿和新生儿并发症的发生与通过日记进行经典血糖监测的患者(对照组)相比不劣效。
TELESUR-GDM 是一项回顾性、单中心、非劣效性研究,包括应用组的 349 名患者和对照组的 295 名患者。主要结局是基于母体、胎儿和新生儿并发症的综合评分。统计分析采用卡方检验或学生 t 检验进行分类或连续变量,Dunnett-Gent 检验用于非劣效性。
在应用组和对照组中,分别有 46.3%和 53.7%的患者观察到并发症。应用程序远程监测与日记监测相比具有非劣效性(优势比=0.79 [95%CI 0.58;1.07],P<0.001)。剖宫产、引产和胰岛素治疗率分别为:应用组 20%,对照组 23%(P=0.4);应用组 36%,对照组 28%(P=0.047);应用组 22%,对照组 23%(P=0.8)。巨大儿、宫内生长受限、新生儿低血糖和新生儿黄疸发生率分别为:应用组 4.3%,对照组 6.1%(P=0.4);应用组 6.9%,对照组 3.1%(P=0.04);应用组 1.7%,对照组 14%(P<0.001);应用组 8.6%,对照组 1.0%(P<0.001)。
与通过日记进行经典血糖监测的患者相比,GDM 血糖远程监测在母体、胎儿和新生儿并发症方面不劣效。尽管观察到更多的新生儿黄疸病例,但新生儿低血糖这一危及生命的事件显著减少。